About PILA PHARMA

PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.

PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.

Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.

FÅ PRESSMEDDELANDEN / GET PRESS RELEASES

News

Pila Pharma AB offentliggör utfall i företrädesemissionen
Läs pressmeddelandet (in Swedish) här

(22 November-2022)

Dorte X. Gram, CEO presenterar på Redeye Investor AW – Göteborg
Please, find the link to the video (in English) here

(10-November-2022)

VD Dorte X. Gram säljer teckningsrätter i Pila Pharma AB och fullföljer teckningsåtagande om att teckna aktier för 250.000 SEK i pågående företrädesemission
Läs pressmeddelandet (in Swedish) här

(10 November-2022)

INBJUDAN TILL TECKNING AV AKTIER I PILA PHARMA AB (PUBL)
Läs Memorandum PDF (in Swedish) här

(02-November-2022)

Pila Pharma AB offentliggör memorandum avseende kommande företrädesemission av aktier
Läs pressmeddelandet (in Swedish) här

(02 November-2022)

Delårsrapport 1 JULI – 30 SEPTEMBER 2022
Läs rapporten PDF (in Swedish) här

(26-October-2022)

Pila Pharma delårsrapport för 1 juli – 30 september 2022
Läs pressmeddelandet (in Swedish) här

Pila Pharma publishes interim report July 1 – September 30, 2022
Read the press release (in English) here

(26-October-2022)

Rättelse: Saknad MAR-etikett och felaktig information om sista dag för handel i Bolagets aktie med rätt till deltagande i Företrädesemissionen i tidigare pressmeddelande
Läs pressmeddelandet (in Swedish) här

(25-October-2022)

Pila Pharma genomför 13 veckors säkerhetsstudier på råttor utan biverkningar under doseringsfasen
Läs pressmeddelandet (in Swedish) här

Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase
Read the press release (in English) here

(11-October-2022)

Delårsrapport 1 april – 30 juni 2022
Läs rapporten PDF (in Swedish) här

(26-August-2022)

Pila Pharma delårsrapport för 1 april – 30 juni 2022
Läs pressmeddelandet (in Swedish) här

Pila Pharma publishes interim report April 1 – June 30, 2022
Read the press release (in English) here

(26-August-2022)

Pila Pharma AB erhåller särläkemedelsstatus i USA
Läs pressmeddelandet (in Swedish) härPila Pharma AB is granted Orphan Drug Designation status in the USA
Read the press release (in English) here

(15-July-2022)

VD Dorte X. Gram ökar sitt innehav i Pila Pharma AB
Läs pressmeddelandet (in Swedish) här

CEO Dorte X. Gram increases holding in Pila Pharma AB
Read the press release (in English) here

(01-July-2022)

Pila Pharma AB inleder toxikologiska studier
Läs pressmeddelandet (in Swedish) här

Pila Pharma AB initiates toxicological studies
Read the press release (in English) here

(30-June-2022)

A quick personal Friday update from founder and CEO Dorte X. Gram! We hope you all have a great weekend! 🙏🏼🧡💊

Please, find the link to the video (in English) on Linkedin or Facebook

(17-June-2022)

Kommuniké från årsstämma i Pila Pharma AB 2022

Läs pressmeddelandet (in Swedish) här

(07-June-2022)

🇩🇰 🤝🏼 🇸🇪
We’re delighted to be back at the wonderful Børsen with Dansk Erhverv, Medicon Valley Alliance Øresundsinstituttet next Monday, May 30th to discuss regional success, collaboration, challenges and more! 🟠

(23-May-2022)

Dorte’s presentation from last weeks visit to Redeye Investor forum is now online. Please find a link below for a brief update and a good Q&A

Please, find the link to the video (in English) here

(16-May-2022)

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Läs pressmeddelandet (in Swedish) här

(09-May-2022)

Our friends at BIOSTOCK caught our CEO Dorte X. Gram for some comments regarding our good Q1 results and our Orphan Drug Designation request!

Have a read in both English and Swedish 😃

(06-May-2022)

Late last week Redeye had a brief interview with our CEO, Dorte X. Gram regarding the last quarterly report and recent significant changes and developments in Pila.

Please, find the link to the video (in English) here

(03-May-2022)

Delårsrapport 1 januari – 31 mars 2022
Läs rapporten PDF (in Swedish) här

(26-April-2022)

Pila Pharma delårsrapport för 1 januari – 31 mars 2022
Läs pressmeddelandet (in Swedish) här

PILA PHARMA publishes interim report January 1 – March 31, 2022
Read the press release (in English) here

(26-April-2022)

Pila Pharma AB tillkännager certifiering av API
Läs pressmeddelandet (in Swedish) här

Pila Pharma AB announces certification of API
Read the press release (in English) here

(25-April-2022)

Pila Pharma bygger pipeline – ansöker om Orphan Drug Designation i USA
Läs pressmeddelandet (in Swedish) här

Pila Pharma builds pipeline – applies for Orphan Drug Designation in the USA
Read the press release (in English) here

(22-April-2022)

We’re really proud that Malmö stad has selected us as finalist in the Life Science category for the Malmö Business Price Award 2022.

Here, our CEO Dorte X. Gram first found high-risk-investors who dared thinking big and PILA PHARMA was kicked off to provide a future better treatment of diabetes!

Läs (in Swedish) här

(05-April-2022)

Årsredovisning för 2021
Läs rapporten PDF (in Swedish) här

(23-March-2022)

Pila Pharma AB publicerar årsredovisning för 2021
Läs pressmeddelandet (in Swedish) här

Pila Pharma AB publishes annual report for 2021
Read the press release (in English) here